PMI conducts a series of in vitro and in vivo studies on smoke-free products, following Good Laboratory Practice (GLP), to determine whether the reduced levels of HPHCs lead to a reduced toxicity compared with cigarette smoke.
PMI takes toxicological assessment one step further by using a new area of science known as systems toxicology. Systems toxicology helps determine whether reduced toxicity leads to reduced risk in laboratory models. Systems toxicology allows a detailed assessment of the disease-relevant biological mechanisms affected by exposure to toxicants. It relies on state-of-the-art high-throughput experimental technologies and advanced computational sciences.
First, systems toxicology is applied to identify the biological mechanisms that are altered by cigarette smoke, capturing this knowledge in biological network models. These models are then used to analyze the datasets for product assessment, allowing comparisons between the network alterations caused by the aerosols of smoke-free products and those caused by cigarette smoke. Furthermore, the approach allows quantitative comparison of the overall biological impact of these exposures in the context of toxicological and disease endpoints.